Targeting the ERK Signaling Pathway in Melanoma

The discovery of the role of the RAS/RAF/MEK/ERK pathway in melanomagenesis and its progression have opened a new era in the treatment of this tumor. Vemurafenib was the first specific kinase inhibitor approved for therapy of advanced melanomas harboring BRAF-activating mutations, followed by dabraf...

Descripción completa

Detalles Bibliográficos
Autores principales: Savoia, Paola, Fava, Paolo, Casoni, Filippo, Cremona, Ottavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472057/
https://www.ncbi.nlm.nih.gov/pubmed/30934534
http://dx.doi.org/10.3390/ijms20061483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472057/
https://www.ncbi.nlm.nih.gov/pubmed/30934534
http://dx.doi.org/10.3390/ijms20061483

Ejemplares similares